Latest Content

Tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis.

Sarah Sammons, MD, discusses how pumitamig’s dual-protein targets position it as a unique agent within the TNBC treatment arena.

PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

Ulka Vaishampayan, MD, FASCO, discusses different novel therapies in development for renal cell carcinoma.

The phase 3 TALAPRO-3 study evaluating talazoparib plus enzalutamide HRR gene–mutated mCSPC met its primary end point.

A new gene-editing approach developed at UCSF treated leukemia, multiple myeloma, and sarcoma in mice by precisely reprogramming immune cells with no external manufacturing required.

Nicole Lamanna, MD, discusses both CLL 17 and FLAIR studies and their significance for chronic lymphocytic leukemia.

Lutetium Lu 177 vipivotide tetraxetan was active after treatment with sipuleucel-T in real-world mCRPC.

However, a trend towards OS benefit was observed when treatment with cabozantinib was deferred until after disease progression vs administered upfront.

David B. Solit, MD, discusses ongoing efforts to develop ADCs and other novel treatment approaches beyond EV plus pembrolizumab in urothelial cancer.

Distinct tumor-immune ecologies helpful for distinguishing stable and progressive disease in NSCLC have been identified by Moffitt Cancer Center.

The regulatory agency green lit the use of MyChoice CDx as a companion diagnostic for niraparib in advanced ovarian cancer

First-line ficerafusp alfa at 2000 mg every 2 weeks plus pembrolizumab was deemed safe and effective in recurrent or metastatic HPV-negative HNSCC.